Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Poster De Conférence Année : 2020

Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation

Résumé

Introduction: Pirfenidone is indicated in the treatment of idiopathic pulmonary fibrosis (IPF) and is now available in tablets instead of capsules. Objective: To describe tolerance, discontinuation and switch rate of capsules/tablets of pirfenidone in France. Methods: Retrospective analysis of the RaDiCo-ILD cohort in patients (pts) who received at least one dose of pirfenidone (2017-2019). Results: A total of 288 pts were treated with pirfenidone including 162 who newly initiated pirfenidone. There were no meaningful differences between the baseline characteristics (gender, age at inclusion/at diagnosis) by formulation of the 256 pts treated with pirfenidone during the potential switch. A total of 44.9% (95% CI 38.8-51.0) pts switched from capsule to tablet formulation and 4.7% from tablet to capsule. Overall, mean treatment duration was 21.5 months (±18.7) and median (Q1; Q3) was 16.2 [6.3; 29.3] with a mean dose of 2106.7 (±460.7)mg/day; 119/256 pts (46.5%) discontinued treatment, 81/119 pts (68.1%) for intolerance and 21/119 pts (10.1%) for ineffectiveness; as shown in the figure there were globally less discontinuations in the tablets and switch groups vs. the capsules only group. Conclusion: Our study shows real-life data in patients with IPF treated with or switching between the two dosage forms of pirfenidone (capsule or tablet).
Fichier principal
Vignette du fichier
Doc2.pdf (534.09 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

inserm-04056683 , version 1 (03-04-2023)

Identifiants

Citer

Vincent Cottin, Sonia Guéguen, Stéphane Jouneau, Hilario Nunes, Bruno Crestani, et al.. Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation. ERS International Congress 2020 abstracts, Sep 2020, virtuel, France. European Respiratory Society, pp.1853, ⟨10.1183/13993003.congress-2020.1853⟩. ⟨inserm-04056683⟩
12 Consultations
11 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More